Vizarsin (sildenafil)
Generic
- Region
- 🇪🇺 EU
- Active substance
- sildenafil
- Company
- KRKA tovarna zdravil d.d. Novo mesto
- Status
- Authorised
- Therapeutic area
- Erectile Dysfunction
- CHMP opinion
- Thu 25 Jun 2009
- EU approval
- Mon 21 Sep 2009
- Designations
- Generic
- Application
- EMEA/H/C/001076
- ATC
- G04BE03
- Official record
- www.ema.europa.eu
Indication
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Vizarsin to be effective, sexual stimulation is required.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Viagra Authorised · Viatris EESV
- 🇪🇺 Revatio Authorised · Viatris EESV
- 🇪🇺 Mysildecard Authorised · Viatris Limited
- 🇪🇺 Sildenafil Actavis Authorised · Actavis Group PTC ehf
- 🇪🇺 Granpidam Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Sildenafil Teva Authorised · Teva B.V.
- 🇪🇺 Sildenafil ratiopharm Authorised · Ratiopharm GmbH
- 🇪🇺 Sildenafil FGK Application withdrawn · FGK Representative Service GmbH
- 🇪🇺 Patrex Withdrawn · Pfizer Limited
- 🇺🇸 Vybrique Approved · Ibsa
Follow Vizarsin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.